These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 28178157)
1. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. Montanier N; Joubert-Zakeyh J; Pétorin C; Montoriol PF; Maqdasy S; Kelly A Medicine (Baltimore); 2017 Feb; 96(6):e6062. PubMed ID: 28178157 [TBL] [Abstract][Full Text] [Related]
2. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351 [TBL] [Abstract][Full Text] [Related]
5. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
16. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377 [TBL] [Abstract][Full Text] [Related]
17. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Sorbye H; Kong G; Grozinsky-Glasberg S Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429 [TBL] [Abstract][Full Text] [Related]
18. Additional hepatic Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
20. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. Ranade R; Basu S J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]